Most people encounter growth hormone peptides one at a time — someone mentions Ipamorelin, or they see CJC-1295 in a protocol, or they read about Sermorelin at a men's health clinic. They get a piece of the picture without understanding how it fits into the whole.
Before evaluating any individual compound, it helps to understand what category it belongs to, how that category works mechanically, and what the evidence base for that category actually looks like.
What "Secretagogue" Actually Means
A growth hormone secretagogue (GHS) is any compound that stimulates the pituitary gland to produce and release its own growth hormone. GH secretagogues are fundamentally different from exogenous HGH — recombinant human growth hormone — which injects synthetic GH directly into the body and progressively suppresses the pituitary's natural production. The distinction matters: GH secretagogues work with the body's endocrine system; exogenous HGH supplants it. The Peptide Guides
This difference affects the GH release pattern (pulsatile vs. flat), long-term pituitary function, side effect profile, cost, and how the body utilizes the growth hormone it receives.
What most people don't realize is that "growth hormone secretagogue" is an umbrella term covering compounds that work through entirely different receptor systems. GHRH analogs work through the GHRH receptor, providing relatively physiological pituitary stimulation with minimal peripheral effects. GHRPs and ghrelin mimetics work through the GH secretagogue receptor (GHSR), also known as the ghrelin receptor, with broader tissue distribution. Two different doors into the same room. Thepeptidecatalog
The GHRH Analog Branch
Growth hormone-releasing hormone (GHRH) is the peptide your hypothalamus naturally produces to signal the pituitary to release GH. GHRH analogs mimic that signal. They act on specific GHRH receptors, promoting episodic GH release that is regulated by natural feedback mechanisms, including somatostatin inhibition. The pituitary responds, releases GH in a pulse, and the normal suppression signals kick in. The feedback loop stays intact. PRG
The three compounds most commonly discussed in this branch are Sermorelin, CJC-1295, and Tesamorelin — in order of escalating clinical validation.
Sermorelin
Sermorelin is a synthetic 29-amino-acid peptide that mirrors the active portion of human GHRH. It stimulates the pituitary to release growth hormone in a pulsatile, physiological pattern and was originally FDA-approved for diagnostic use and pediatric growth hormone deficiency. The brand product was discontinued in 2008. The manufacturer discontinued production for commercial reasons — not safety concerns — and it is no longer available as an FDA-approved drug, though it may be obtained through compounding pharmacies. PlexusDxWikipedia
Sermorelin has the shortest half-life of the major GHRH analogs — roughly 11 to 12 minutes — producing a sharp, clean GH pulse that closely mirrors the body's natural pulsatile release pattern. It's the most accessible entry point in the GHRH analog category and carries the clearest regulatory history of any compounded GH peptide, but its clinical evidence base is thinner than either of the options below. HealingMaps
CJC-1295
CJC-1295 is a modified GHRH analog that comes in two meaningfully different forms. The version without DAC (Drug Affinity Complex), also called Mod GRF 1-29, has a half-life of approximately 30 minutes to 2 hours, triggering a brief but potent GH pulse before quickly clearing from the system. The version with DAC is a different pharmacological animal entirely. BC9
The DAC modification binds albumin in the blood, extending its half-life to approximately 8 days and allowing once-weekly dosing. Clinical trials of the DAC version showed significant GH and IGF-1 elevation with preserved pulsatile patterns. A landmark study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single administration of CJC-1295 with DAC in human subjects produced sustained GH and IGF-1 elevations lasting up to 6 days, with mean GH concentrations increasing 2–10 fold over baseline. RethinkPeptidesSourcepeptides
The tradeoff of the DAC version is that sustained stimulation is less physiologically natural than pulse-based release. Some researchers have raised concerns that tonic stimulation may blunt the amplitude of individual GH pulses over time. Neither version of CJC-1295 has FDA approval, and formal trial data in humans is limited compared to Tesamorelin. Iron Peak Peptides
Tesamorelin
Tesamorelin is the outlier in this category in the most important way: it is the only GHRH analog with FDA approval and completed phase III trial data. It received FDA approval in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy. In a pooled analysis of 806 participants across two phase III trials, it reduced visceral adipose tissue by approximately 15.4% versus placebo at 26 weeks (p<0.001). Superpower
The cognition data adds another dimension. A randomized, double-blind, placebo-controlled trial at the University of Washington enrolled 152 adults between 55 and 87 years of age, who self-administered daily subcutaneous injections of tesamorelin (1 mg/d) or placebo for 20 weeks, with cognitive testing covering executive function, verbal memory, and visual memory. Tesamorelin improved executive function (p = 0.005), as measured by Task Switching accuracy, Stroop Color-Word Interference reaction time, Self-Ordered Pointing Test accuracy, and Word Fluency. PubMedPeptideJournal
The GHRP Branch
The GHRP pathway involves a receptor called the Growth Hormone Secretagogue Receptor (GHS-R), also known as the ghrelin receptor. Ghrelin is a hormone produced primarily in the stomach — while best known for its role in hunger signaling, researchers discovered it also binds to receptors on pituitary somatotrophs and stimulates growth hormone release. This means the pituitary can receive GH-releasing signals from two completely independent sources: the brain (via GHRH) and the gut (via ghrelin). Alpha Peptides
GHRPs are synthetic compounds that activate this ghrelin receptor pathway. The key compounds are Ipamorelin, GHRP-2, and GHRP-6 — and the differences between them come down almost entirely to selectivity.
Ipamorelin
Research published by Raun et al. (1998) specifically characterized Ipamorelin as the first GHRP to demonstrate GH release potency comparable to GHRP-6 while showing significantly less prolactin and ACTH stimulation — a profile described as representing a new generation of selective GH secretagogues. That selectivity is Ipamorelin's defining characteristic. Ipamorelin is highly selective for growth hormone release, while GHRP-6 and GHRP-2 also affect cortisol and prolactin levels. MiPeptidosAlpha Peptides
In practice, this means Ipamorelin produces a clean GH pulse without the appetite surge, cortisol elevation, or prolactin effects that come with older GHRPs. It's generally considered the best-tolerated compound in the GHRP category — the first choice when isolated GH axis activation is the goal.
GHRP-2
GHRP-2 is not just slightly stronger than GHRP-6 — it is also meaningfully cleaner. It achieves higher peak GH output while producing less appetite stimulation and a more moderate cortisol profile. Both peptides are significantly less selective than Ipamorelin, which produces GH release without meaningful effects on appetite, cortisol, or prolactin. GHRP-2 is the appropriate choice when maximum GH amplitude is the priority and the tradeoffs are understood. Peptidepedia
GHRP-6
GHRP-6 is the original GHRP, with the longest history of research use. It produces robust GH release alongside notable ACTH, cortisol, and prolactin co-stimulation. Its most distinct feature is a pronounced appetite-stimulating effect — mediated directly through ghrelin receptor activation — that kicks in within minutes of injection. For anyone focused on body composition and caloric control, that's a meaningful liability. For anyone trying to drive appetite in a clinical or performance context, it's a tool. Spartan Peptides
Oral Secretagogues: MK-677
MK-677 (ibutamoren) occupies a unique corner of the GHS category. It is an orally active growth hormone secretagogue developed by Merck in the 1990s, originally investigated as a treatment for growth hormone deficiency, muscle wasting, and osteoporosis. Despite promising phase II clinical trial data, MK-677 was never approved by the FDA and remains an investigational compound. Mkibutamoren
MK-677 is functionally in the GHRP/ghrelin bucket — GHSR-driven — not the GHRH bucket. This explains why it shares the appetite-stimulating properties common to ghrelin receptor agonists. Its main advantage over injectable GHRPs is obvious: it's a pill. A 40–72% sustained increase in IGF-1 has been documented across multiple human trials, with a standard dose of 25mg/day taken at bedtime. ThepeptidecatalogPeptideDeck
The tradeoffs are real. In a 12-month randomized trial in healthy older adults, MK-677 increased fat-free mass by about 1.1 kg but did not improve strength and worsened insulin sensitivity (Nass et al., 2008, Annals of Internal Medicine). The health effects of long-term use have not been fully investigated, and researchers stopped at least one clinical trial early because of concerns about heart failure. For men with any metabolic concerns around glucose or insulin, this is not a neutral compound. BodySpecHealthy Male
Why Combination Protocols Exist
Because the two categories act on different receptors, combining one from each is studied for synergistic GH release — this is the entire rationale behind CJC-1295 + Ipamorelin stacks. The combination engages both upstream pathways at once. A GHRH analog without a GHRP produces a modest GH pulse. The combination produces substantially more GH than either alone because they activate complementary receptor pathways. ThepeptidecatalogThe Peptide Guides
This is why the no-DAC version of CJC-1295 is generally preferred for stacking over the DAC version — the short-acting variant produces synchronized, discrete GH pulses that work with Ipamorelin's timing. The DAC version's sustained baseline stimulation is a different pharmacological model.
What to Think About Before Any of These
IGF-1 monitoring applies to the entire category. Every compound discussed here raises IGF-1 to some degree — that's largely how they produce their effects. Elevated IGF-1 over time carries theoretical oncological considerations that haven't been fully characterized in long-term human data. Anyone with a history of malignancy needs to approach this entire category with their physician.
Pulsatile matters. Most researchers and clinicians favor GHRH analogs and selective GHRPs specifically because they preserve the body's natural GH pulse pattern. The exception is CJC-1295 with DAC, which produces sustained tonic stimulation — a different pharmacological model with different implications.
Clinical evidence is uneven across the category. Tesamorelin has phase III trial data and FDA approval. Sermorelin has an established compounding history and prior approval. CJC-1295 has limited human data. MK-677 has human trials but no approval and a concerning long-term safety signal. Ipamorelin, GHRP-2, and GHRP-6 have preclinical and some human evidence but no formal approval pathway. Those aren't equally strong foundations.
Medical oversight is non-negotiable. Baseline IGF-1 before starting, monitoring during, and a physician who understands the GH axis aren't optional safeguards — they're the difference between a thoughtful protocol and a guessing game.
What's Happening at the FDA Right Now
The peptide category has been in regulatory flux for the past two years, and if you're following GH secretagogues specifically, the picture is worth understanding accurately — because most coverage gets it wrong.
In September 2023, the FDA moved CJC-1295, Ipamorelin, GHRP-2, GHRP-6, and a dozen other peptides into Category 2 of its compounding list, effectively prohibiting them from being compounded by licensed pharmacies for human use. That ban drew sustained legal and clinical pushback, and the FDA ultimately agreed to submit the compounds for formal review by its Pharmacy Compounding Advisory Committee (PCAC). Springfieldptwellness
CJC-1295, Ipamorelin, and AOD-9604 had their PCAC hearings in late 2024. The committee voted against adding them to the authorized compounding list. That's the current status for those compounds — an unfavorable recommendation, with no second review yet scheduled. PeptideClarity
The meeting most people are watching is July 23–24, 2026. The PCAC will review seven peptides for 503A compounding eligibility: BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide (DSIP), Semax, and Epitalon on July 24. These are not GH secretagogues — they sit in different areas of the peptide category. A second round covering five additional compounds is scheduled before February 2027. Amanecia Health
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. PubMed
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed
- Jetté L, et al. Human GRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005;146(7):3253–62. PubMed
- Baker LD, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420–29. PubMed
- Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291–4304. PubMed
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601–11. PubMed
- Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–45. PubMed
